CI Investments Inc. Has $41.19 Million Position in AbbVie Inc. $ABBV

CI Investments Inc. trimmed its position in AbbVie Inc. (NYSE:ABBV) by 12.2% during the third quarter, HoldingsChannel.com reports. The fund owned 177,879 shares of the company’s stock after selling 24,811 shares during the period. CI Investments Inc.’s holdings in AbbVie were worth $41,186,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. Mathes Company Inc. bought a new stake in AbbVie in the third quarter valued at approximately $232,000. Accuvest Global Advisors boosted its position in shares of AbbVie by 1.3% during the third quarter. Accuvest Global Advisors now owns 4,151 shares of the company’s stock worth $961,000 after purchasing an additional 52 shares in the last quarter. Focus Partners Advisor Solutions LLC grew its holdings in shares of AbbVie by 2.8% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 36,230 shares of the company’s stock valued at $8,203,000 after buying an additional 996 shares during the period. Kingsview Wealth Management LLC increased its position in shares of AbbVie by 1.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 70,947 shares of the company’s stock valued at $16,427,000 after buying an additional 824 shares in the last quarter. Finally, Elo Mutual Pension Insurance Co raised its stake in AbbVie by 2.9% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 205,301 shares of the company’s stock worth $47,535,000 after buying an additional 5,860 shares during the period. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.08% of the stock is currently owned by corporate insiders.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $234.16 on Tuesday. The stock has a 50 day moving average price of $224.47 and a 200 day moving average price of $223.47. The stock has a market capitalization of $414.04 billion, a PE ratio of 99.22, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research analyst reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Finally, Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.